Differences in efficacy, differences in providers: Results from a hazard analysis of medical abortion

Contraception

Volumn 69, Issue 2, 2004, Pages 157-163

  Hedley, Allison ^a   Trussell, James ^a   Turner, Abigail Norris ^b   Coyaji, Kurus ^c   Ngoc, Nguyen Thi Nhu ^d   Winikoff, Beverly ^e   Ellertson, Charlotte ^f  

^a PRINCETON UNIVERSITY   (United States)

^b IL   (United States)

^c KEM HOSPITAL   (India)

^d Vietnam   (Viet Nam)

^e GYNUITY HEALTH PROJECTS   (United States)

^f IBIS REPRODUCTIVE HEALTH   (United States)

Author keywords

Hazard analysis; Medical abortion; Vacuum aspiration

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; EDUCATION; EXPERIENCE; FEMALE; GESTATIONAL AGE; HAZARD ASSESSMENT; HUMAN; HUMAN EXPERIMENT; INDUCED ABORTION; SAMPLE SIZE; THERAPEUTIC ABORTION; VACUUM ASPIRATION;

EID: 0842324630     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2003.11.010     Document Type: Article

References (11)

1. Kahn J., Becker B., MacIsaa L., et al. The efficacy of medical abortion a meta-analysis . Contraception. 61:2000;29-40.
2. Coyaji K., Elul B., Krishna U., et al. Mifepristone abortion outside the urban research hospital setting in India. Lancet. 357:2001;120-122.
3. Ngoc N., Winikoff B., Clark S., et al. Safety, efficacy and acceptability of mifepristone-misoprostol medical abortion in Vietnam. Int Fam Plann Perspect. 25:1999;10-14. ,33.
4. Spitz I., Bardin C., Benton L., Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 338:1998;1241-1247.
5. Winikoff B., Sivin I., Coyaji K., et al. Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India a comparative trial of mifepristone-misoprostol versus surgical abortion . Am J Obstet Gynecol. 176:1997;431-437.
6. Peyron R, Ulmann A, Baulieu E. [Mifepristone (RU486) in 1995: Present status, prospectives]. Presse Med 1995;24:295-8 (in French).
7. Zieman M., Guillebaud J., Weisberg E., et al. Contraceptive efficacy and cycle control with the Ortho Evra™/Evra™ transdermal system The analysis of pooled data . Fertil Steril. 77:(Suppl):2002;S13-18.
8. Holt V.L., Cushing-Haugen K.L., Daling J.R. Body weight and risk of oral contraceptive failure. Obstet Gynecol. 99:2002;820-827.
9. Newhall E., Winikoff B. Abortion with mifepristone and misoprostol regimens, efficacy, acceptability, and future directions . Am J Obstet Gynecol. 183:2000;S44-53.
10. Clark S., Ellertson C., Winikoff B. Is medical abortion acceptable to all American women the impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion . J Am Med Womens Assoc. 55:2000;177-182.
11. Urquhart D., Templeton A., Shinewi F., et al. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK multicentre study - final results. Contraception. 55:1997;1-5.